{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:30:40Z","timestamp":1791088240456,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/mol.0b013e32836139df","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T15:31:41Z","timestamp":1366126301000},"page":"246-250","source":"Crossref","is-referenced-by-count":58,"title":["Microsomal transfer protein inhibition in humans"],"prefix":"10.1097","volume":"24","author":[{"given":"Marina","family":"Cuchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20211004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0005-2760(96)00168-3","article-title":"Microsomal triglyceride transfer protein.","volume":"1345","author":"Wetterau","year":"1997","journal-title":"Biochimic Biophys Acta"},{"key":"R3-11-20211004","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia.","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"R4-11-20211004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/365065a0","article-title":"Cloning and gene defects in microsomal triglyceride transfer protien associated with abetalipoproteinemia.","volume":"365","author":"Sharp","year":"1993","journal-title":"Nature"},{"key":"R5-11-20211004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev.nutr.20.1.663","article-title":"The role of the microsomal triglygeride transfer protein in abetalipoproteinemia.","volume":"20","author":"Berriot-Varoqueaux","year":"2000","journal-title":"Ann Rev Nutr"},{"key":"R6-11-20211004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein.","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"issue":"Suppl","key":"R7-11-20211004","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1194\/jlr.R800090-JLR200","article-title":"The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism.","volume":"50","author":"Ginsberg","year":"2009","journal-title":"J Lipid Res"},{"key":"R8-11-20211004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1084\/jem.20050183","article-title":"Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells.","volume":"202","author":"Dougan","year":"2005","journal-title":"J Exp Med"},{"key":"R9-11-20211004","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1172\/JCI42703","article-title":"Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.","volume":"120","author":"Zeissig","year":"2010","journal-title":"J Clin Invest"},{"key":"R10-11-20211004","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1073\/pnas.93.21.11991","article-title":"An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells.","volume":"93","author":"Jamil","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-11-20211004","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1021\/bi9924009","article-title":"Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist.","volume":"39","author":"Bakillah","year":"2000","journal-title":"Biochemistry"},{"key":"R12-11-20211004","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1021\/jm010294e","article-title":"Diaminoindanes as microsomal triglyceride transfer protein inhibitors.","volume":"44","author":"Ksander","year":"2001","journal-title":"J Med Chem"},{"key":"R13-11-20211004","first-page":"562","article-title":"Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms.","volume":"5","author":"Chang","year":"2002","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R14-11-20211004","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.","volume":"44","author":"Chandler","year":"2003","journal-title":"J Lipid Res"},{"key":"R15-11-20211004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1248\/bpb.28.247","article-title":"Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation.","volume":"28","author":"Ueshima","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"R16-11-20211004","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.282.5389.751","article-title":"An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.","volume":"282","author":"Wetterau","year":"1998","journal-title":"Science"},{"key":"R17-11-20211004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(01)01419-4","article-title":"MTP inhibitor decreases plasma cholesterol levels in LDL receptordeficient WHHL rabbits by lowering the VLDL secretion.","volume":"431","author":"Shiomi","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"Suppl II","key":"R19-11-20211004","first-page":"601","article-title":"Inhibition of postprandial fat absorption with the MTP inhibitor BAY-13-9952 (Abstract).","volume":"102","author":"Stein","year":"2000","journal-title":"Circulation"},{"key":"R20-11-20211004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R22-11-20211004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2004-822985","article-title":"Homozygous familial hypercholesterolemia and its management.","volume":"4","author":"Marais","year":"2004","journal-title":"Semin Vasc Med"},{"key":"R23-11-20211004","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"R24-11-20211004","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"R25-11-20211004","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1194\/jlr.M300020-JLR200","article-title":"Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER.","volume":"44","author":"Liao","year":"2003","journal-title":"J Lipid Res"},{"key":"R26-11-20211004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-11-20211004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"R28-11-20211004","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"R29-11-20211004","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1096\/fasebj.11.13.9367349","article-title":"Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene.","volume":"11","author":"Lin","year":"1997","journal-title":"Faseb J"},{"key":"R30-11-20211004","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/hep.1840040621","article-title":"Morphologic features of the liver in abetalipoproteinemia.","volume":"4","author":"Avigan","year":"1984","journal-title":"Hepatology"},{"key":"R31-11-20211004","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1172\/JCI112727","article-title":"Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia.","volume":"78","author":"Dullaart","year":"1986","journal-title":"J Clin Invest"},{"key":"R32-11-20211004","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/0016-5085(89)90651-3","article-title":"Hepatic peroxisomal abnormalities in abetalipoproteinemia.","volume":"97","author":"Collins","year":"1989","journal-title":"Gastroenterology"},{"key":"R33-11-20211004","first-page":"41","article-title":"Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy.","volume":"132","author":"Hegele","year":"1985","journal-title":"Can Med Assoc J"},{"key":"R34-11-20211004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(19)32931-2","article-title":"Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis.","volume":"67","author":"Partin","year":"1974","journal-title":"Gastroenterology"},{"key":"R35-11-20211004","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archneur.1980.00500590083015","article-title":"Abetalipoproteinemia. Report of two cases and review of therapy.","volume":"37","author":"Illingworth","year":"1980","journal-title":"Arch Neurol"},{"key":"R36-11-20211004","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004310050882","article-title":"Persistence of the intestinal defect in abetalipoproteinaemia after liver transplantation.","volume":"157","author":"Braegger","year":"1998","journal-title":"Eur J Pediatr"},{"key":"R37-11-20211004","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90033-H","article-title":"Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia.","volume":"101","author":"Black","year":"1991","journal-title":"Gastroenterology"},{"key":"R38-11-20211004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2010.03.039","article-title":"Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia.","volume":"139","author":"Amaro","year":"2010","journal-title":"Gastroenterology"},{"key":"R40-11-20211004","doi-asserted-by":"crossref","first-page":"E828","DOI":"10.1152\/ajpendo.00453.2003","article-title":"Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis.","volume":"286","author":"Buettner","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R41-11-20211004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1124\/jpet.110.173807","article-title":"Pharmacological characterization of diethyl-2-(3-dimethylcarbamoyl-4-(4-trifluoromethylbiphenyl-2-carbonyl)aminop henylacetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein.","volume":"336","author":"Mera","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-11-20211004","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.bmcl.2011.05.099","article-title":"Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide.","volume":"21","author":"Robinson","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"R43-11-20211004","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.110.177527","article-title":"A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile.","volume":"337","author":"Kim","year":"2011","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:23:59Z","timestamp":1633314239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e32836139df","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}